Drugs / SKB571
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06725381 | Dec 2024 → Dec 2026 expected | cancer | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT07622186 | Jul 2026 → Dec 2028 expected | non-small cell lung carcinoma | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07668154 | Jul 2026 → Sep 2028 expected | head and neck squamous cell carcinoma | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07564466 | Jun 2026 → Aug 2027 expected | digestive system neoplasm | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07308106 | Apr 2026 → Jun 2027 expected | non-small cell lung carcinoma | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT07230405 | Jan 2026 → Jan 2028 expected | non-small cell lung carcinoma | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SKB571 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07668154 ↗ |
| Route | Intravenous | “Intravenous(IV) infusion(Q3W)” NCT07564466 ↗ |